MARKET HIGHLIGHTS CONSUMER 🔸 Lululemon ( $LULU): Q4 adj. EPS $6.14 (est. $5.85); revs +13% y/y to $3.61B (est. $3.57B). Q1 comp sales +3% (+4% constant dollar). Q4 Americas comps flat; Intl +20%. Sees Q1 EPS $2.53-$2.58 (est. $2.78) & revs $2.34B-$2.36B (est. $2.39B). 🔸 Oxford ( $OXM): Q4 adj. EPS $1.37 (est. $1.27), sales $391M (est. $383.94M). Guides Q1 sales $375M-$395M (est. $401.18M), EPS $1.70-$1.90 (est. $2.79). Sees FY revs $1.49B-$1.53B (est. $1.54B), EPS $4.60-$5.00 (est. $6.81). ENERGY, INDUSTRIALS & MATERIALS 🔸 AAR ( $AIR): Q3 adj. EPS $0.99 (est. $0.96), revs +20% y/y to $678M (est. $699.13M). Adj. EBITDA +39% y/y to $81M; margin 12% (10.3% prior). Op margin 10.5% (5.8% y/y). 🔸 Argan ( $AGX): Q4 EPS $2.22 (est. $1.15), EBITDA $39.3M (est. $19.4M), revs $232.5M (est. $197.5M). 🔸 KULR ( $KULR): Q4 EPS ($0.02) in line, op. inc. ($3.54M) (est. $3.046M), revs $3.37M (est. $2.901M). Bitcoin holdings $20.28M (as of 12/31/24). 🔸 Nippon ( $NPSCY)/US Steel (X): Offering more investment to Trump admin to close $14B merger – Semafor. 🔸 Schneider ( $SNDR): Downgraded to Neutral at BofA, tgt cut to $25 (from $34) on weaker demand, tariff uncertainty, and pricing pressure. FINANCIALS 🔸 Voya ( $VOYA): Downgraded to Underperform at BofA, tgt cut to $71 (from $79). Estimates imply $7.10-$7.90 EPS for 2025 (vs. est. $8.14). HEALTHCARE 🔸 Beam ( $BEAM): FDA clears NDA for BEAM-302 (alpha-1 antitrypsin deficiency). 🔸 CureVac ( $CVAC): EU patent upheld with amendments. 🔸 Kodiak ( $KOD): Q4 EPS ($0.84) (est. ($0.88)); cash runway into 2026. TECH, MEDIA & TELECOM 🔸 CoreWeave ( $CRWV): 37.5M share IPO at $40, below $47-$55 range; reduced from 49M shares. 🔸 Braze ( $BRZE): Acquires OfferFit for $325M (cash & stock). 🔸 Civeo ( $CVEO): Approves share buyback up to 10%.

MORNING RECAP • $LOW Q3: EPS $2.89 (beat consensus $2.81), sales $20.2B (beat consensus $19.92B); Q3 comp sales -1.1% due to weak DIY demand, offset by storm sales and growth in Pro and online. Revised full-year outlook: sales $83B-$83.5B, EPS $11.80-$11.90. • $ADM: Q3 profit fell due to weak North American crush margins; Nutrition segment expects better Q4 but not as high as Q3 2024. • $CTRN: Appointed Ken Seipel as CEO; Q3 sales $179.1M, comp sales up 5.7%. • $WEN: Ken Cook appointed as CFO, effective December 2, 2024. • $XPEV: Q3 revenue $1.39B, above estimates; EPS loss of $1.90, worse than expected $1.71 loss. Q4 revenue forecast at $2.09B-$2.21B; launched P7+ sedan. • $ACM increases buyback to $1B; Q4 EPS $1.27, revenue $4.11B, slightly below consensus. FY25 EPS forecast $5.00-$5.20. • $AMCR to acquire $BERY in $8.4B stock deal at a 10% premium. • $AVAV acquiring BlueHalo in $4.1B stock deal. Oil prices dip as Johan Sverdrup field restarts post-outage. • $ERII launches $50M stock repurchase. • $NPSCY engages with $X stakeholders to push for $15B acquisition. • $SYAXF to merge with $PLL in an all-stock deal, valuing the new entity at $623M. • $SYM Q4 operating income exceeds expectations; sets Q1 revenue guidance at $495-515M. U.S. defense stocks rise following Russia's updated nuclear policy and threats. • $DOC ups 2024 FFO guidance to $1.80-$1.82, citing strong portfolio performance. • $INCY stock drops after pausing a phase 2 study due to preclinical findings. • $MDT Q2 revenue up 5.2% to $8.4B, raises FY25 EPS outlook slightly. • $OMCL issues $150M in convertible senior notes. • $SYRE plans to offer $200M in common stock and warrants. • $AMD: Darla Smith resigns as Chief Accounting Officer on November 15. • $GOOGL stock declines as DOJ plans to demand the sale of Chrome browser. • $INTC: Efforts to distribute manufacturing grants under the Chips Act are stalled, with most of the $39B yet to be disbursed. • $MSTR aims to raise $1.75B through convertible senior notes. • $MCHP: Ganesh Moorthy retires; Steve Sanghi appointed as interim CEO. • $SMCI stock rises after appointing BDO USA as auditor and seeking Nasdaq compliance extension